Why the study?
Asymptomatic community-acquired respiratory viral carriage before lung transplantation has not been studied.
Does asymptomatic community-acquired respiratory viral carriage pre-lung transplant worsen early post-transplant outcomes in adult lung transplant recipients?
Does asymptomatic community-acquired respiratory viral carriage pre-lung transplant worsen early post-transplant outcomes in adult lung transplant recipients?
Asymptomatic respiratory viral carriage before lung transplantation does not appear to be associated with worse short-term post-transplant outcomes.
Asymptomatic pre-LTx CARV positivity was not associated with increased PGD or other early risks; leaves open whether routine testing should alter transplant timing.
Asymptomatic community-acquired respiratory viral (CARV) carriage before lung transplantation (LTx) has not been studied. This study analyzed CARV carriage pre-LTx and its impact on early post-LTx outcome. This retrospective cohort study included adult LTx recipients at UMC Groningen from January 2017 to August 2023. Pre-LTx viral swabs were routinely tested for CARV. The primary outcome was incidence of primary graft dysfunction (PGD) at 48 or 72 h post-LTx. Secondary outcomes included mechanical ventilation duration, ICU stay, hospital length of stay (LOS), 30- and 90-day mortality, and early rejection therapy. Of 222 recipients, 23 (10.4%) tested positive for a CARV, most commonly rhinovirus (n=10). PGD grade 3 occurred in 14.3% of CARV-positive vs. 9.1% of CARV-negative recipients (p=0.434). No differences were observed in secondary outcomes. Our study provides early data suggesting that asymptomatic carriage may not be associated with worse short-term outcomes.
No takes yet. Share an insight, caveat, or question.
Bolt et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: